Literature DB >> 15292212

Imperfect CAG repeats form diverse structures in SCA1 transcripts.

Krzysztof Sobczak1, Wlodzimierz J Krzyzosiak.   

Abstract

The expanded CAG repeat in the coding sequence of the spinocerebellar ataxia type 1 (SCA1) gene is responsible for SCA1, one of the hereditary human neurodegenerative diseases. In the normal SCA1 alleles usually 1-3 CAT triplets break the continuity of the CAG repeat tracts. Here we show what is the structural role of the CAU interruptions in the SCA1 transcripts. Depending on their number and localization within the repeat tract the interruptions either enlarge the terminal loop of the hairpin formed by the repeats, nucleate the internal loops in its stem structure, or force the repeats to fold into two smaller hairpins. Thus, the interruptions destabilize the CAG repeat hairpin, which is likely to decrease its ability to participate in the putative RNA pathogenesis mechanism driven by the long CAG repeat hairpins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292212     DOI: 10.1074/jbc.M405130200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex.

Authors:  Sybille Krauss; Nadine Griesche; Ewa Jastrzebska; Changwei Chen; Désiree Rutschow; Clemens Achmüller; Stephanie Dorn; Sylvia M Boesch; Maciej Lalowski; Erich Wanker; Rainer Schneider; Susann Schweiger
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

2.  Insights into the mutational history and prevalence of SCA1 in the Indian population through anchored polymorphisms.

Authors:  Uma Mittal; Sangeeta Sharma; Rupali Chopra; Kalladka Dheeraj; Pramod Kr Pal; Achal K Srivastava; Mitali Mukerji
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

3.  Structural diversity of triplet repeat RNAs.

Authors:  Krzysztof Sobczak; Gracjan Michlewski; Mateusz de Mezer; Elzbieta Kierzek; Jacek Krol; Marta Olejniczak; Ryszard Kierzek; Wlodzimierz J Krzyzosiak
Journal:  J Biol Chem       Date:  2010-02-16       Impact factor: 5.157

4.  Interruptions in the expanded ATTCT repeat of spinocerebellar ataxia type 10: repeat purity as a disease modifier?

Authors:  Tohru Matsuura; Ping Fang; Christopher E Pearson; Parul Jayakar; Tetsuo Ashizawa; Benjamin B Roa; David L Nelson
Journal:  Am J Hum Genet       Date:  2005-11-15       Impact factor: 11.025

Review 5.  CAG repeat RNA as an auxiliary toxic agent in polyglutamine disorders.

Authors:  Marzena Wojciechowska; Wlodzimierz J Krzyzosiak
Journal:  RNA Biol       Date:  2011-07-01       Impact factor: 4.652

Review 6.  Pathogenesis of spinocerebellar ataxias viewed from the RNA perspective.

Authors:  Gracjan Michlewski; Wlodzimierz J Krzyzosiak
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

7.  Atomic resolution structure of CAG RNA repeats: structural insights and implications for the trinucleotide repeat expansion diseases.

Authors:  Agnieszka Kiliszek; Ryszard Kierzek; Wlodzimierz J Krzyzosiak; Wojciech Rypniewski
Journal:  Nucleic Acids Res       Date:  2010-08-11       Impact factor: 16.971

8.  Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats.

Authors:  Kaalak Reddy; Mandy Tam; Richard P Bowater; Miriam Barber; Matthew Tomlinson; Kerrie Nichol Edamura; Yuh-Hwa Wang; Christopher E Pearson
Journal:  Nucleic Acids Res       Date:  2010-11-04       Impact factor: 16.971

Review 9.  Role and Perspective of Molecular Simulation-Based Investigation of RNA-Ligand Interaction: From Small Molecules and Peptides to Photoswitchable RNA Binding.

Authors:  Daria V Berdnikova; Paolo Carloni; Sybille Krauß; Giulia Rossetti
Journal:  Molecules       Date:  2021-06-03       Impact factor: 4.411

Review 10.  RNA toxicity in polyglutamine disorders: concepts, models, and progress of research.

Authors:  Agnieszka Fiszer; Wlodzimierz J Krzyzosiak
Journal:  J Mol Med (Berl)       Date:  2013-03-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.